HIGHLIGHTS
- who: Report et al. from the Dermatology, Albert Einstein College of Medicine, Bronx, USA have published the article: Review began 05/29/2022 Review ended 06/14/2022 Published 06/16/2022 u00a9 Copyright, in the Journal: (JOURNAL) of June/16,/2022
- what: As rebastinib inhibits multiple tyrosine kinases and VEGFR-2, the authors propose that T-cell function was likely impaired in the patient who developed a verruca vulgaris eruption.
SUMMARY
Rebastinib is a novel antineoplastic agent that targets several tyrosine kinases, including the angiopoietin-1 receptor TIE-2, vascular . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.